Modification of polypeptides with a fatty acid chain to bind to HSA has been most successful clinically for insulin and glucagon-like peptide (GLP)-1 agonists to treat diabetes, e.g., Tresiba® (insulin degludec), Levemir® (insulin determir), Ozempic® (semaglutide) and Victoza®/Saxenda® (liraglutide) [67,93]. The gene discussed is INS; the disease is diabetes mellitus.